Emergent BioSolutions (EBS) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Emergent BioSolutions Inc.	'
Entity Central Index Key	'0001367644	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'Yes	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	37,552,024
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$242,249	$179,338
Accounts receivable	44,111	60,587
Inventories	62,533	14,643
Income tax receivable, net	8,262	5,651
Prepaid expenses and other current assets	26,477	12,896
Total current assets	383,632	273,115
Property, plant and equipment, net	304,211	264,240
In process research and development	50,300	41,800
Intangible assets, net	64,464	30,148
Goodwill	41,301	13,954
Deferred tax assets - long-term, net	17,043	0
Other assets	8,340	3,373
Total assets	869,291	626,630
Current liabilities:	'	'
Accounts payable	39,351	27,521
Accrued expenses and other current liabilities	4,688	1,252
Accrued compensation	26,850	24,615
Contingent purchase consideration, current portion	2,488	1,341
Provision for chargebacks	2,139	0
Deferred tax liability-current portion, net	88	88
Deferred revenue, current portion	5,813	1,834
Total current liabilities	81,417	56,651
Contingent purchase consideration, net of current portion	16,745	15,278
Long-term indebtedness	251,000	62,000
Deferred tax liability long-term, net	0	1,419
Deferred revenue, net of current portion	5,815	0
Other liabilities	1,176	2,117
Total liabilities	356,153	137,465
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 37,960,977 shares issued and 37,548,024, shares outstanding at September 30, 2014; 37,036,996 shares issued and 36,624,043, shares outstanding at December 31, 2013	38	37
Treasury stock, at cost, 412,953 common shares at both September 30, 2014 and December 31, 2013	-6,119	-6,119
Additional paid-in capital	264,877	247,637
Accumulated other comprehensive loss	-3,810	-3,465
Retained earnings	258,152	251,528
Total Emergent BioSolutions Inc. stockholders' equity	513,138	489,618
Noncontrolling interest in subsidiaries	0	-453
Total stockholders' equity	513,138	489,165
Total liabilities and stockholders' equity	$869,291	$626,630

Consolidated_Balance_Sheets_Un1

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,960,977	37,036,996
Common stock, shares outstanding (in shares)	37,548,024	36,624,043
Treasury stock (in shares)	412,953	412,953

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Product sales	$84,457	$76,297	$198,493	$172,252
Contract manufacturing	9,433	0	21,346	0
Contracts, grants and collaborations	44,064	12,805	82,324	42,386
Total revenues	137,954	89,102	302,163	214,638
Operating expenses:	'	'	'	'
Cost of product sales and contract manufacturing	32,423	20,063	85,927	42,706
Research and development	44,207	28,937	111,864	89,939
Selling, general and administrative	30,292	21,955	90,936	62,484
Income from operations	31,032	18,147	13,436	19,509
Other income (expense):	'	'	'	'
Interest income	59	88	130	121
Interest expense	-1,810	0	-7,066	-14
Other income (expense), net	420	58	2,254	93
Total other income (expense)	-1,331	146	-4,682	200
Income before provision for income taxes	29,701	18,293	8,754	19,709
Provision for income taxes	7,869	4,802	2,129	4,667
Net income	21,832	13,491	6,625	15,042
Net loss attributable to noncontrolling interest	0	0	0	871
Net income attributable to Emergent BioSolutions Inc.	$21,832	$13,491	$6,625	$15,913
Income per share - basic	$0.58	$0.37	$0.18	$0.44
Income per share - diluted	$0.49	$0.36	$0.17	$0.44
Weighted-average number of shares - basic (in shares)	37,507,220	36,272,579	37,261,357	36,129,183
Weighted-average number of shares - diluted (in shares)	46,557,163	37,015,529	37,885,194	36,504,230

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statements of Comprehensive Income (Unaudited) [Abstract]	'	'	'	'
Net income attributable to Emergent BioSolutions Inc.	$21,832	$13,491	$6,625	$15,913
Foreign currency translations, net of tax	-559	11	-345	627
Comprehensive income	$21,273	$13,502	$6,280	$16,540

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$6,625	$15,042
Adjustments to reconcile to net cash provided by operating activities:	'	'
Stock-based compensation expense	9,454	8,459
Depreciation and amortization	24,286	13,547
Current and deferred income taxes	1,817	4,667
Non-cash development expenses from joint venture	0	-348
Change in fair value of contingent purchase consideration	3,216	349
Write off of debt issuance costs	1,831	0
Excess tax benefits from stock-based compensation	-5,566	-1,949
Other	541	-19
Changes in operating assets and liabilities:	'	'
Accounts receivable	36,106	65,950
Inventories	4,729	-1,164
Income taxes	-4,447	-6,927
Prepaid expenses and other assets	-10,845	-3,532
Accounts payable	-11,176	-1,622
Accrued expenses and other liabilities	1,026	-240
Accrued compensation	-208	-4,164
Provision for chargebacks	-308	0
Deferred revenue	3,416	278
Net cash provided by operating activities	60,497	88,327
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-14,621	-34,420
Acquisition of Healthcare Protective Products Division	0	-24,120
Acquisition of Cangene Corporation, net of acquired cash	-178,167	0
Net cash used in investing activities	-192,788	-58,540
Cash flows from financing activities:	'	'
Proceeds from convertible debenture, net of debt issuance costs	241,654	0
Proceeds from other long-term debt obligations	1,000	0
Issuance of common stock subject to exercise of stock options	10,656	2,505
Excess tax benefits from stock-based compensation	5,566	1,949
Principal payments on long-term indebtedness	-62,000	-3,352
Contingent obligation payments	-1,691	0
Net cash provided by financing activities	195,185	1,102
Effect of exchange rate changes on cash and cash equivalents	17	6
Net increase in cash and cash equivalents	62,911	30,895
Cash and cash equivalents at beginning of period	179,338	141,666
Cash and cash equivalents at end of period	$242,249	$172,561

Summary_of_significant_account

Summary of significant accounting policies	9 Months Ended
	Sep. 30, 2014
Summary of significant accounting policies [Abstract]	'
Summary of significant accounting policies	'
	1. Summary of significant accounting policies
	Basis of presentation and consolidation
	The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
	In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2014; the results of operations and comprehensive income for the three and nine months ended September 30, 2014 and 2013; and cash flows for the nine months ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
	There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC, during the nine months ended September 30, 2014, except for additions to the Company's accounting policies for revenue recognition and inventories related to the Cangene Corporation ("Cangene") acquisition (Note 2) and revenue recognition for the MorphoSys AG ("MorphoSys") collaboration (Note 4).
	Revenue recognition
	The Company recognizes revenues from product sales if four basic criteria have been met:
		§	there is persuasive evidence of an arrangement;
		§	delivery has occurred or title has passed to the Company's customer;
		§	the fee is fixed or determinable; and
		§	collectability is reasonably assured.
	All revenues from product sales are recorded net of applicable allowances for sales rebates, special promotional programs, and discounts. The Company estimates allowances for revenue reducing obligations using a combination of information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations. Provisions for estimated rebates and other allowances, such as discounts and promotional and other credits, are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and contract terms, and actual discounts offered.
	The Company markets and sells its Biosciences products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost ("WAC"). Additionally, the Company enters into agreements with indirect customers for a contracted price that is less than the WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, purchase the Company's products from the wholesalers. Under these agreements with wholesalers, the Company guarantees to credit them for the difference between the WAC and the indirect customers' contracted price. This credit is referred to as a chargeback. Adjustments to the Company's chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company makes subjective judgements primarily based on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or as an adjustment to past sales, or both.
	The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized when the appropriate revenue recognition criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.
	Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting are recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting are deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract..
	The Company generates revenues from its August 2014 collaboration agreement with MorphoSys. The collaboration provides for sharing of development and clinical costs, with the Company responsible for 36% of such costs and MorphoSys responsible for the remainder. In the event the Company's share of the total cost for a given quarter exceeds 36% of the total costs for the project, the Company records a net receivable in its financial statements equal to the difference between the Company's costs and 36% of the total costs for the period, and reduces research and development expense in this amount. If the Company's share of the cost for the quarterly period is less than 36% of the total costs for the project, the Company records a net payable in its financial statements equal to the difference between the Company's costs and 36% of the total costs, and records additional research and development expenses in this amount.
	Inventories
	Inventories are stated at the lower of cost or market with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to expired inventory. Costs of purchased inventories are recorded using weighted-average costing. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2014
Acquisitions [Abstract]	'
Acquisitions	'
	2. Acquisitions
	Cangene Corporation
	On February 21, 2014, the Company acquired 100% of the voting interest of Cangene for $3.24 per share in cash (on a fully-diluted basis), which represents a total purchase price of $221.8 million. This transaction was accounted for by the Company under the acquisition method of accounting, with the Company as the acquirer. Under the acquisition method of accounting, the assets and liabilities of Cangene were recorded as of the acquisition date, at their respective fair values, and combined with those of the Company. This acquisition diversified the product portfolio of the Company's Biodefense and Biosciences divisions and expanded the Company's manufacturing capabilities.
	The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014. As of the date of this filing, the valuation of acquired intangible assets, deferred taxes and other fair value adjustments are not complete as the Company is obtaining and analyzing additional information related to the aforementioned items. As such, the purchase price allocation is subject to change.
	(in thousands)	21-Feb-14
	Fair value of tangible assets acquired and liabilities assumed:
	Cash	$	43,631
	Accounts receivable		19,649
	Inventory (i)		52,619
	Prepaid expenses and other assets		2,375
	Property, plant and equipment		40,264
	Deferred taxes, net		18,371
	Income tax receivable		2,940
	Accounts payable and accrued liabilities		(22,918	)
	Provision for chargebacks		(2,447	)
	Contingent purchase consideration		(1,089	)
	Deferred revenue		(6,378	)
	Total fair value of tangible assets acquired and liabilities assumed		147,017
	Acquired in-process research and development		8,500
	Acquired intangible assets		40,400
	Goodwill		25,883
	Total purchase price	$	221,800
	(i) Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.
	During the three months ended September 30, 2014 the Company updated its fair value determination for contingent purchase consideration and the provision for chargebacks resulting in a reduction to goodwill of $5.9 million and a reduction to contingent purchase consideration and the provision of chargebacks.
	The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:
					Amortization
					Period
	( in thousands)	Amount			in years
	Corporate Trade Name	$	2,800			5
	Marketed Products		8,300			10
	Licensed Products		3,300			7
	Biodefense Products		20,400			12
	Contract Manufacturing		5,600			8
	Total identified intangible assets	$	40,400
	The Company determined the estimated fair value of the intangible assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs that are developed by the Company using estimates and assumptions of the respective market and market penetration of the Company's products.
	A portion of the assets acquired from Cangene consisted of intangible assets. The Marketed Products intangible asset consists of WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] and VARIZIG® (Varicella Zoster Immune Globulin (Human)]. The Licensed Products intangible asset primarily consists of HepaGam B® (Hepatitis B Immune Globulin Intravenous (Human). The Biodefense intangible asset consist of BATTM [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-Equine], AIGIV (Anthrax Immune Globulin Intravenous (Human)) and VIGIV (Vaccinia Immune Globulin Intravenous (Human)). The Contract Manufacturing intangible asset is primarily related to contract manufacturing contracts with current and expected future third-party customers.
	The Company estimated the fair value of the Marketed, Licensed and Biodefense Product intangible assets using the income approach with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value these intangible assets. The projected cash flows from these Marketed, Licensed and Biodefense Product intangible assets were based on key assumptions including: estimates of revenues and operating profits; the life of the potential commercialized product and associated risks; and risks related to the viability of and potential alternative treatments in any future target markets.
	The Company estimated the fair value of the Contract Manufacturing intangible asset using the income approach with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value this intangible asset. The projected cash flows from the Contract Manufacturing intangible asset were based on key assumptions including: estimates of revenues and operating profits; and viability of attaining/maintaining future third-party manufacturing relationships with the Company's customers.
	The Company estimated the fair value of the Corporate Trade Name intangible asset using the relief of royalty method with a present value discount rate of 15%, which is based on the estimated weighted-average cost of capital for companies with profiles substantially similar to that of Cangene. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value this intangible asset.
	The weighted average amortization period of the intangible assets from the Cangene acquisition is 115 months. For the three and nine months ended September 30, 2014, the Company recorded amortization expense of $1.0 million and $2.6 million, respectively, for intangible assets acquired from Cangene, which has been recorded in cost of product sales and contract manufacturing. Amortization expense of $620,000 and $1.5 million, respectively, was recorded within the Biosciences segment for the three and nine months ended September 30, 2014. Amortization expense of $425,000 and $1.0 million, respectively, was recorded within the Biodefense segment for the three and nine months ended September 30, 2014.
	The intangible asset associated with in-process research and development ("IPR&D") acquired from Cangene is the IXINITY product candidate. Management determined that the estimated acquisition-date fair value of intangible assets related to IPR&D was $8.5 million. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. The Company estimated the fair value using a present value discount rate of 16%, which is based on the estimated weighted-average cost of capital for companies with that profiles substantially similar to that of Cangene and IPR&D assets at a similar stage of development as IXINITY. This is comparable to the estimated internal rate of return for the acquisition and represents the rate that market participants would use to value the IPR&D. The projected cash flows for IXINITY was based on key assumptions including: estimates of revenues and operating profits, considering its stage of development on the acquisition date; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a product candidate, such as obtaining marketing approval from the U.S. Food and Drug Administration ("FDA") and other regulatory agencies; and risks related to the viability of and potential for alternative treatments in any future target markets. IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts (see Note 6).
	The Company recorded approximately $25.9 million in goodwill related to the Cangene acquisition, representing the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired. None of the goodwill generated from the Cangene acquisition is expected to be deductible for tax purposes.
	The Company has incurred transaction costs related to the Cangene acquisition of approximately $3.7 million for the nine months ended September 30, 2014, which has been recorded in selling, general and administrative expenses within the Company's Biosciences segment. The Company has incurred to date a total of $7.0 million in transaction costs associated with the Cangene acquisition through September 30, 2014, of which $3.3 million was incurred in the second half of 2013.
	From the date of acquisition to September 30, 2014, the Company has recognized revenue of $82.1 million and a net loss attributable to Emergent BioSolutions Inc. of $4.8 million from the operations of Cangene.
	The following pro forma information is presented as if the acquisition had occurred on January 1, 2013, and combines the historical results of operations of the Company and Cangene for the nine month periods ended September 30, 2014 and 2013.
		September 30,
	(in thousands)	2014			2013
	Pro forma revenue	$	329,642		$	304,164
	Pro forma net income	$	9,109		$	468
	Healthcare Protective Products Division
	On August 1, 2013, the Company acquired substantially all of the assets and liabilities of Healthcare Protective Products Division ("HPPD"), a division of Bracco Diagnostics Inc. ("Bracco"), for $25.9 million in cash along with contingent purchase consideration obligations to Bracco. The assets and liabilities acquired include HPPD's product, RSDL, and a majority of the customer and distributor agreements associated with RSDL along with $1.5 million of manufacturing equipment. In addition, the Company assumed a $1.5 million liability associated with the Canadian Technology Development Fund ("TDF"). The acquisition diversified the product portfolio of the Biodefense segment by adding product sales from RSDL.
	The contingent purchase consideration obligation due to Bracco is based on a percentage of RSDL net sales, ranging from 5-10%, for the period August 1, 2013 through July 31, 2028. At August 1, 2013, the contingent purchase consideration obligation was recorded at a fair value of $16.2 million. The Level 3 fair value of this obligation is based on management's assessment of the potential future realization of the contingent purchase consideration payments. This assessment is based on inputs that have no observable market. The obligation is measured using the income approach (a discounted cash flow model).
	The total purchase price is summarized below:
	(in thousands)
	Amount of cash paid to Bracco Diagnostics Inc.	$	25,873
	Fair value of contingent purchase consideration at date of acquisition		16,232
	Total purchase price	$	42,105
	The table below summarizes the allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013.
	(in thousands)
	Acquired intangible assets	$	32,099
	Goodwill		9,916
	Acquired equipment		1,543
	Other		11
Assumed liabilities		(1,464	)
Total purchase price	$	42,105
During the nine months ended September 30, 2014, the Company updated its purchase price to include an assumed liability from the TDF resulting in additional goodwill of $1.5 million.
A substantial portion of the assets acquired from Bracco consisted of intangible assets associated with RSDL. As of the date of acquisition, the Company recorded intangible assets of approximately $28.6 million related to RSDL, which is being amortized over 8 years, and $3.5 million related to a manufacturing agreement with Bracco, which is being amortized over 3 years. For the three and nine months ended September 30, 2014, the Company recorded $1.2 million and $3.5 million, respectively, of amortization expense for intangible assets acquired from Bracco which was recorded in cost of product sales and contract manufacturing within the Company's Biodefense segment. The weighted average remaining amortization period for the intangible assets is 77 months.
The Company recorded approximately $9.9 million in goodwill related to the HPPD acquisition representing the purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired. This goodwill is included in the Company's biodefense segment. None of the goodwill generated from the HPPD acquisition is expected to be deductible for tax purposes.
The Company has determined the historical results of HPPD were not significant to the Company's results of operations, and as such no proforma disclosures have been presented.

Fair_value_measurements

Fair value measurements	9 Months Ended
	Sep. 30, 2014
Fair value measurements [Abstract]	'
Fair value measurements	'
	3. Fair value measurements
	The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:
		At September 30, 2014
	(in thousands)		Level 1			Level 2		Level 3		Total
	Assets:
	Investment in money market funds (1)		$	154,669		$	-	$	-	$	154,669
	Total assets		$	154,669		$	-	$	-	$	154,669
	Liabilities:
	Contingent purchase consideration		$	-		$	-	$	19,233	$	19,233
	Total liabilities		$	-		$	-	$	19,233	$	19,233
		At December 31, 2013
	(in thousands)		Level 1			Level 2		Level 3		Total
	Assets:
	Investment in money market funds (1)		$	37,701		$	-	$	-	$	37,701
	Total assets		$	37,701		$	-	$	-	$	37,701
	Liabilities:
	Contingent purchase consideration		$	-		$	-	$	16,619	$	16,619
	Total liabilities		$	-		$	-	$	16,619	$	16,619
	(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.
	For the periods ended September 30, 2014 and 2013, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.
	The fair value of contingent purchase consideration obligations are based on management's assessment of changes as a result of adjustments to the discount rates and updates in the assumed and actual achievement of future net sales for RSDL and HepaGam B, which are inputs that have no observable market (Level 3). For the three and nine months ended September 30, 2014, the contingent purchase consideration obligation increased by $1.6 million and  $3.2 million, respectively, primarily due to an adjustment to the actual and expected timing of RSDL and HepaGam B sales. This increase resulted in a charge that is classified in the Company's statement of operations as cost of product sales and contract manufacturing.
	The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2014.
	(in thousands)
	Balance at December 31, 2013		$	16,619
	Expense (income) included in earnings			3,216
	Settlements			(1,691	)
	Purchases, sales and issuances			1,089
	Transfers in/(out) of Level 3			-
	Balance at September 30, 2014		$	19,233
	Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a nonrecurring basis. During the nine months ended September 30, 2014, the assets acquired and liabilities assumed as part of the Cangene acquisition (Note 2) and the evaluation of the IXINITY IPR&D asset for impairment (Note 6) were measured at fair value on a nonrecurring basis. During the nine months ended September 30, 2013, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis.

MorphoSys_Collaboration_Agreem

MorphoSys Collaboration Agreement	9 Months Ended
	Sep. 30, 2014
Morphosys Collaboration Agreement [Abstract]	'
Morphosys Collaboration Agreements	'
	4. MorphoSys collaboration agreement
	In August 2014, the Company entered into a collaboration agreement ("MorphoSys Agreement") with MorphoSys for the joint worldwide development and commercialization of MOR209/ES414, a targeted immunotherapeutic protein, constructed using the Company's proprietary ADAPTIR technology platform, which activates host T-cell immunity specifically against prostate cancer cells expressing prostate specific membrane antigen, an antigen commonly overexpressed on prostate cancer cells.
	In accordance with the terms of the MorphoSys Agreement, the Company received a nonrefundable $20 million upfront payment and may receive up to $163 million in additional contingent payments, of which $80.0 million and $83.0 million, respectively, are due upon the achievement of specified development and regulatory milestones. The Company has determined that payments for the achievement of the development and regulatory milestones identified in the agreement that may become due will be deemed substantive milestones and will be accounted for as revenue in the period in which the milestone is achieved.
	MorphoSys and the Company will jointly fund further development of MOR209/ES414, with the Company responsible for 36% of the total development cost and MorphoSys responsible for the remainder. The Company's funding requirement is capped at $186 million. The Company will retain commercialization rights in the U.S. and Canada, with a tiered royalty obligation to MorphoSys, ranging from mid-single digits up to 20%. MorphoSys will gain worldwide commercialization rights excluding the U.S. and Canada, with a low single digit royalty obligation to the Company.The Company's current obligations under the collaboration includes the performance of non-clinical, clinical, manufacturing and regulatory activities.
	The Company has evaluated the MorphoSys Agreement and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.The Company determined there were two units of accounting under the collaboration agreement with MorphoSys: (1) the delivered license to further develop and commercialize MOR209/ES414 and (2) undelivered items related to development services. The Company determined that the license had standalone value as the drug candidate has been developed and is currently Phase I clinical trial ready, MorphoSys possesses the knowledge, technology, skills, experience and infrastructure necessary to complete all further development of the drug through commercialization, and additionally MorphoSys has the right to further sublicense the product. The Company allocated the $20 million upfront payment to the two units of accounting using the relative selling price method. The Company determined the estimated selling price for the license using the income approach and a discount rate of 12%. The estimated selling price includes unobservable inputs (Level 3), such as estimates of revenues and operating margins; the time and resources needed to complete the development and approval of the product candidate; and the risk related to the viability of and potential for alternative treatments. The Company determined the estimated selling price of the development services unit of accounting based on the estimated number of full-time equivalent personnel at the contractual rate as defined in the MorphoSys Agreement, which represents the approximate terms of other service related contracts both entered by the Company and observed generally through other collaboration negotiations. The allocation resulted in $15.3 million of the upfront payment being allocated to the license and $4.7 million being allocated to the development services. The Company determined the license fee unit of accounting was delivered on the date the MorphoSys agreement was executed and therefore has recognized revenue of $15.3 million, which is included in contracts, grants and collaborations revenues within the Company's Biosciences segment. Revenue related to the undelivered item will be recognized as the services are performed. The current estimated service period for the undelivered item under the MorphoSys Agreement is through 2022.
	The amount allocable to the units of accounting is limited to the amount that is not contingent upon the delivery of additional items or meeting other specified performance conditions (the noncontingent amount). As such, the Company excluded from the allocable arrangement consideration the milestone payments and royalties regardless of the probability of receipt.
	As of September 30, 2014, accounts receivable related to the MorphoSys Agreement was $450,000. As of September 30, 2014, deferred revenue related to the MorphoSys Agreement consisted of $590,000 and $4.1 million of current and long-term deferred revenue, respectively.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventories [Abstract]	'
Inventories	'
	5. Inventories
	Inventories consist of the following:
		September 30,		December 31,
	(in thousands)	2014		2013
	Raw materials and supplies	$	16,089	$	2,656
	Work-in-process		31,383		9,819
	Finished goods		15,061		2,168
	Total inventories	$	62,533	$	14,643

Intangible_assets_inprocess_re

Intangible assets, in-process research and development and goodwill	9 Months Ended
	Sep. 30, 2014
Intangible assets, in-process research and development and goodwill [Abstract]	'
Intangible assets, in-process research and development and goodwill	'
	6. Intangible assets, in-process research and development and goodwill
	As of September 30, 2014, the Company had $50.3 million of IPR&D assets, which are included in the Biosciences business segment. This includes $41.8 million related to the Company's otlertuzumab product candidate and $8.5 million related to the Company's IXINITY product candidate. On July 29, 2014, the FDA issued a complete response letter for the New Drug Application ("NDA") of IXINITY. The complete response letter requested additional analyses of data from completed studies and noted deficiencies in the chemistry, manufacturing, and controls section of the license application, all of which must be resolved before approval can be granted by the FDA. The Company determined that the FDA's response to its NDA is a potential indicator of impairment of the related IXINITY IPR&D asset. The Company performed its interim impairment analysis and concluded its estimated fair value for the IXINITY IPR&D asset was in excess of carrying value, therefore the Company determined there was no impairment of the IXINITY IPR&D asset as of September 30, 2014. The determination of fair value involved unobservable inputs, such as estimates of future revenues and operating profits, probabilities of success and discount rates. The Company believes these inputs represent the highest and best use of the IXINITY IPR&D asset.
	Intangible assets consist of the following:
					Manufacturing			Corporate			Marketed			Licensed			Biodefense			Contract
	(in thousands)	RSDL			Agreement			Tradename			Products			Products			Products			Manufacturing			Total
	Cost basis
	Balance at December 31, 2013	$	28,621		$	3,478		$	-		$	-		$	-		$	-		$	-		$	32,099
	Additions		-			-			2,800			8,300			3,300			20,400			5,600			40,400
	Balance at September 30, 2014	$	28,621		$	3,478		$	2,800		$	8,300		$	3,300			20,400		$	5,600		$	72,499
	Accumulated amortization
	Balance at December 31, 2013	$	(1,468	)	$	(483	)	$	-		$	-		$	-		$	-		$	-		$	(1,951	)
	Amortization		(2,640	)		(870	)		(338	)		(502	)		(285	)		(1,026	)		(423	)		(6,084	)
	Balance at September 30, 2014	$	(4,108	)	$	(1,353	)	$	(338	)	$	(502	)	$	(285	)	$	(1,026	)	$	(423	)	$	(8,035	)
	Net book value at September 30, 2014	$	24,513		$	2,125		$	2,462		$	7,798		$	3,015		$	19,374			5,177		$	64,464
	The following table is a summary of changes in goodwill:
	(in thousands)	Total
	Cost basis
	Balance at December 31, 2013	$	13,954
	Additions		27,347
	Balance at September 30, 2014	$	41,301

Longterm_debt

Long-term debt	9 Months Ended
	Sep. 30, 2014
Long-term debt [Abstract]	'
Long-term debt	'
	7. Long-term debt
	On January 29, 2014, the Company issued $250.0 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the "Notes"). The Notes bear interest at a rate of 2.875% per year, payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2014. The Notes mature on January 15, 2021, unless earlier purchased by the Company or converted. The conversion rate is equal to 30.8821 shares of common stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $32.38 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest. The Company incurred approximately $8.3 million in debt issuance costs associated with the Notes, which has been capitalized on the consolidated balance sheets and is being amortized over seven years, using the effective interest method.
	On December 11, 2013, the Company entered into a senior secured credit agreement (the "Credit Agreement") with three lending financial institutions (the "Lenders"), led by Bank of America, N.A., as administrative agent. The Credit Agreement originally provided for a revolving credit facility of up to $100.0 million through December 11, 2018 (or such earlier date required by the terms of the Credit Agreement) and a term loan facility of up to $125.0 million to be drawn in full, if at all, on or prior to March 31, 2014. In connection with the Credit Agreement, the Company borrowed $62.0 million under the revolving credit facility primarily to repay obligations under existing loan agreements. On January 29, 2014, in connection with the Company's issuance of the Notes, the unused $125.0 million term loan portion of the Credit Agreement terminated automatically in accordance with the terms of the Credit Agreement. In addition, following the closing of the Notes offering, the Company repaid the $62.0 million outstanding indebtedness under the revolving credit facility, which restored the full $100.0 million revolving credit capacity under this facility. In addition, during the nine months ended September 30, 2014, the Company expensed $1.8 million of debt issuance cost associated with the term loan facility. As of September 30, 2014, no amounts were drawn under the revolving credit facility.
	The Company's payment obligations under the Credit Agreement are secured by a lien on substantially all of the Company's assets, including the stock of all of the Company's subsidiaries, and the assets of the subsidiary guarantors, including mortgages over certain of their real properties, including the Company's large-scale vaccine manufacturing facility in Lansing, Michigan and the Company's product development and manufacturing facility in Baltimore, Maryland.
	The Credit Agreement, as amended, contains affirmative and negative covenants customary for financings of this type. Negative covenants in the Credit Agreement limit the Company's ability to, among other things: incur indebtedness (other than the issuance of the Notes) and liens; dispose of assets; make investments including loans, advances or guarantees; and enter into certain mergers or similar transactions. The Credit Agreement also contains financial covenants, tested quarterly and in connection with any triggering events under the Credit Agreement that include the maintenance of: (1) a minimum consolidated debt service coverage ratio of 2.50 to 1.00, (2) a maximum consolidated leverage ratio for the period ending on or prior to September 30, 2014 of 4.00 to 1.00, for the measurement period ending December 31, 2014 of 3.75 to 1.00, and thereafter of 3.50 to 1.00, (3) a maximum consolidated senior leverage ratio of 2.00 to 1.00 and (4) a minimum liquidity requirement of $50 million. Upon the occurrence and continuance of an event of default under the Credit Agreement, the commitments of the lenders to make loans under the Credit Agreement may be terminated and the Company's payment obligations under the Credit Agreement may be accelerated. The events of default under the Credit Agreement include, among others, subject in some cases to specified cure periods: payment defaults; inaccuracy of representations and warranties in any material respect; defaults in the observance or performance of covenants; bankruptcy and insolvency related defaults; the entry of a final judgment in excess of a threshold amount; change of control; and the invalidity of loan documents relating to the Credit Agreement.

Equity_awards

Equity awards	9 Months Ended
	Sep. 30, 2014
Equity awards [Abstract]	'
Equity awards	'
	8.  Equity awards
	As of September 30, 2014, the Company had two stock-based employee compensation plans, the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan") (together, the "Emergent Plans").
	On May 22, 2014, the Company's shareholders approved an amendment to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 4,000,000. As part of this amendment, awards of restricted stock units granted after May 22, 2014 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 2.3 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 1,000,000.
	The following is a summary of stock option award activity under the Emergent Plans:
		2006 Plan					2004 Plan
		Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
	Outstanding at December 31, 2013		3,633,146		$	17.01		53,156	$	8.86	$	23,148,738
	Granted		1,116,721			27.49		-		-
	Exercised		(663,256	)		16.66		-		-
	Forfeited		(92,549	)		19.69		-		-
	Outstanding at September 30, 2014		3,994,062		$	19.94		53,156	$	8.86	$	14,289,421
	Exercisable at September 30, 2014		2,086,114		$	17.76		53,156	$	8.86	$	9,446,930
	The following is a summary of restricted stock unit award activity under the 2006 Plan:
		Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
	Outstanding at December 31, 2013		789,951		$	16.53	$	18,246,611
	Granted		558,362			27.49
	Vested		(345,072	)		17.76
	Forfeited		(44,275	)		19.66
	Outstanding at September 30, 2014		958,966		$	22.32	$	20,435,565

Variable_interest_entities

Variable interest entities	9 Months Ended
	Sep. 30, 2014
Variable interest entities [Abstract]	'
Variable interest entities	'
	9. Variable interest entities
	In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company liquidated OETC during the nine month period ending September 30, 2014. In addition, the Company recorded an adjustment related to noncontrolling interest of $453,000 due to the liquidation. This expense was recorded as selling, general and administrative expense within the Company's Biosciences segment.

Earnings_per_share

Earnings per share	9 Months Ended
	Sep. 30, 2014
Earnings per share [Abstract]	'
Earnings per share	'
	10. Earnings per share
	For the three and nine month periods ended September 30, 2014 and 2013, basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.
	For the three and nine month periods ended September 30, 2014, diluted earnings per share is computed using the if-converted method by dividing the adjusted net income by the weighted average number of shares of common stock outstanding during the period. The adjusted net income is adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Company's Notes. The weighted average number of shares-diluted is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.
	For the three and nine months ended September 30, 2013, diluted earnings per share is computed using the treasury method by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.
	The following table presents the calculation of basic and diluted net income per share:
		Three Months Ended September 30,				Nine Months Ended September 30,
	(in thousands, except share and per share data)	2014		2013		2014		2013
	Numerator:
	Net income	$	21,832	$	13,491	$	6,625	$	15,913
	Interest expense applicable to convertible debt, net of tax		917		-		-		-
	Amortization of debt issuance costs, net of tax		203		-		-		-
	Adjusted net income	$	22,952	$	13,491	$	6,625	$	15,913
	Denominator:
	Weighted-average number of shares—basic		37,507,220		36,272,579		37,261,357		36,129,183
	Dilutive securities—equity awards		954,639		742,950		623,837		375,047
	Dilutive securities—convertible debt		8,095,304		-		-		-
	Weighted-average number of shares—diluted		46,557,163		37,015,529		37,885,194		36,504,230
	Income per share-basic	$	0.58	$	0.37	$	0.18	$	0.44
	Income per share-diluted	$	0.49	$	0.36	$	0.17	$	0.44
	For the nine months ended September 30, 2014, there were no adjustments to adjusted net income or dilutive securities associated with the Company's Notes as such adjustments would have been anti-dilutive. For the nine months ended September 30, 2014, outstanding stock options to purchase approximately 1.5 million shares of common stock, along with 8.1 million shares related to the Company's convertible debt, were excluded from the calculation of diluted earnings per share.
	Stock options with exercise prices in excess of the average per share closing price during the period are not considered in the calculation of fully diluted earnings per share. For the three months ended September 30, 2014, approximately 1.5 million stock options were excluded from the calculation of diluted earnings per share. For the three and nine month periods ended September 30, 2013, approximately 1.4 million and 1.5 million stock options, respectively, were excluded from the calculation of diluted earnings per share.

Segment_information

Segment information	9 Months Ended
	Sep. 30, 2014
Segment information [Abstract]	'
Segment information	'
	11. Segment information
	For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is provided to and resources are allocated by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different manufacturing and development processes, along with having separate and distinct sales and marketing processes.
	The Biodefense division is a specialty biopharmaceutical business focused on countermeasures that address Chemical, Biological, Radiological and Nuclear threats and consists of two business units: vaccines and therapeutics, and medical devices. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets hematology/oncology, transplantation and infectious diseases, and consists of three business units, therapeutics, vaccines and contract manufacturing. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.
		Reportable Segments
	(in thousands)	Biodefense		Biosciences			All Other			Total
	Three Months Ended September 30, 2014
	External revenue	$	104,130	$	33,824		$	-		$	137,954
	Net income (loss)		25,182		(496	)		(2,854	)		21,832
	Three Months Ended September 30, 2013
	External revenue	$	89,102	$	-		$	-		$	89,102
	Net income (loss)		27,175		(12,491	)		(1,193	)		13,491
	Nine Months Ended September 30, 2014
	External revenue	$	243,162	$	59,001		$	-		$	302,163
	Net income (loss)		56,305		(43,321	)		(6,359	)		6,625
	Nine Months Ended September 30, 2013
	External revenue	$	213,663	$	975		$	-		$	214,638
	Net income (loss)		56,780		(38,019	)		(2,848	)		15,913

Subsequent_Event

Subsequent Event	9 Months Ended
	Sep. 30, 2014
Subsequent Event (Details) [Abstract]	'
Subsequent Event	'
	Note 12. Subsequent Events
	In October 2014, the Company announced a plan to cease its product development activities in Munich, Germany, close its Princeton, New Jersey sales and marketing office, and sell its Henlow Bay development/manufacturing facility in Winnipeg, Canada. The key drivers for this restructuring include the following:
		§	Reprioritization of the Company's product development portfolio;
		§	Relocation of manufacturing development work for the Company's platform products;
		§	Centralization of laboratory work; and
		§	Centralization of sales and marketing activities.
	The restructuring entails a headcount reduction, sale of facilities and equipment, and the potential impairment of leasehold improvements and certain other equipment. The Company expects to complete this restructuring in the first half of 2015, and estimates that the total cost of the restructuring will be up to $5.0 million.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2014
Summary of significant accounting policies [Abstract]	'
Basis of presentation and consolidation	'
	Basis of presentation and consolidation
	The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
	In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2014; the results of operations and comprehensive income for the three and nine months ended September 30, 2014 and 2013; and cash flows for the nine months ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
	There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC, during the nine months ended September 30, 2014, except for additions to the Company's accounting policies for revenue recognition and inventories related to the Cangene Corporation ("Cangene") acquisition (Note 2) and revenue recognition for the MorphoSys AG ("MorphoSys") collaboration (Note 4).
Revenue recognition	'
	Revenue recognition
	The Company recognizes revenues from product sales if four basic criteria have been met:
		§	there is persuasive evidence of an arrangement;
		§	delivery has occurred or title has passed to the Company's customer;
		§	the fee is fixed or determinable; and
		§	collectability is reasonably assured.
	All revenues from product sales are recorded net of applicable allowances for sales rebates, special promotional programs, and discounts. The Company estimates allowances for revenue reducing obligations using a combination of information received from third parties including market data, inventory reports from major wholesalers, historical information and analysis. These estimates are subject to the inherent limitations of estimates that rely on third-party data, as certain third-party information may itself rely on estimates and reflect other limitations. Provisions for estimated rebates and other allowances, such as discounts and promotional and other credits, are estimated based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and contract terms, and actual discounts offered.
	The Company markets and sells its Biosciences products through commercial wholesalers (direct customers) who purchase the products at a price referred to as the wholesale acquisition cost ("WAC"). Additionally, the Company enters into agreements with indirect customers for a contracted price that is less than the WAC. The indirect customers, such as group-purchasing organizations, physician practice-management groups and hospitals, purchase the Company's products from the wholesalers. Under these agreements with wholesalers, the Company guarantees to credit them for the difference between the WAC and the indirect customers' contracted price. This credit is referred to as a chargeback. Adjustments to the Company's chargeback provisions are made periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company makes subjective judgements primarily based on its evaluation of current market conditions and trade inventory levels related to the Company's products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or as an adjustment to past sales, or both.
	The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's relative selling price and is recognized when the appropriate revenue recognition criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.
	Revenue associated with non-refundable upfront license fees that can be treated as a single unit of accounting are recognized when all ongoing obligations have been delivered. Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting are deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligations under the contract..
	The Company generates revenues from its August 2014 collaboration agreement with MorphoSys. The collaboration provides for sharing of development and clinical costs, with the Company responsible for 36% of such costs and MorphoSys responsible for the remainder. In the event the Company's share of the total cost for a given quarter exceeds 36% of the total costs for the project, the Company records a net receivable in its financial statements equal to the difference between the Company's costs and 36% of the total costs for the period, and reduces research and development expense in this amount. If the Company's share of the cost for the quarterly period is less than 36% of the total costs for the project, the Company records a net payable in its financial statements equal to the difference between the Company's costs and 36% of the total costs, and records additional research and development expenses in this amount.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses (including fixed production-overhead costs) and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off, in the applicable period, the costs related to expired inventory. Costs of purchased inventories are recorded using weighted-average costing. The Company determines normal capacity for each production facility and allocates fixed production-overhead costs on that basis.

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2014
Acquisitions [Abstract]	'
Purchase Price	'
	The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014. As of the date of this filing, the valuation of acquired intangible assets, deferred taxes and other fair value adjustments are not complete as the Company is obtaining and analyzing additional information related to the aforementioned items. As such, the purchase price allocation is subject to change.
	(in thousands)	21-Feb-14
	Fair value of tangible assets acquired and liabilities assumed:
	Cash	$	43,631
	Accounts receivable		19,649
	Inventory (i)		52,619
	Prepaid expenses and other assets		2,375
	Property, plant and equipment		40,264
	Deferred taxes, net		18,371
	Income tax receivable		2,940
	Accounts payable and accrued liabilities		(22,918	)
	Provision for chargebacks		(2,447	)
	Contingent purchase consideration		(1,089	)
	Deferred revenue		(6,378	)
	Total fair value of tangible assets acquired and liabilities assumed		147,017
	Acquired in-process research and development		8,500
	Acquired intangible assets		40,400
	Goodwill		25,883
	Total purchase price	$	221,800
	(i) Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up is estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on expected inventory turnover, which will increase cost of product sales and contract manufacturing during such period.
	During the three months ended September 30, 2014 the Company updated its fair value determination for contingent purchase consideration and the provision for chargebacks resulting in a reduction to goodwill of $5.9 million and a reduction to contingent purchase consideration and the provision of chargebacks.
Fair Value of Intangible Assets	'
	The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:
					Amortization
					Period
	( in thousands)	Amount			in years
	Corporate Trade Name	$	2,800			5
	Marketed Products		8,300			10
	Licensed Products		3,300			7
	Biodefense Products		20,400			12
	Contract Manufacturing		5,600			8
	Total identified intangible assets	$	40,400
Pro Forma Information	'
	The following pro forma information is presented as if the acquisition had occurred on January 1, 2013, and combines the historical results of operations of the Company and Cangene for the nine month periods ended September 30, 2014 and 2013.
		September 30,
	(in thousands)	2014			2013
	Pro forma revenue	$	329,642		$	304,164
	Pro forma net income	$	9,109		$	468
Business Acquisition [Line Items]	'
Purchase Price HPPD [Table Text Block]	'
	The total purchase price is summarized below:
	(in thousands)
	Amount of cash paid to Bracco Diagnostics Inc.	$	25,873
	Fair value of contingent purchase consideration at date of acquisition		16,232
	Total purchase price	$	42,105
Purchase Price Allocation	'
	The total purchase price is summarized below:
	(in thousands)
	Amount of cash paid to Bracco Diagnostics Inc.	$	25,873
	Fair value of contingent purchase consideration at date of acquisition		16,232
	Total purchase price	$	42,105

Fair_value_measurements_Tables

Fair value measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair value measurements [Abstract]	'
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:
		At September 30, 2014
	(in thousands)		Level 1			Level 2		Level 3		Total
	Assets:
	Investment in money market funds (1)		$	154,669		$	-	$	-	$	154,669
	Total assets		$	154,669		$	-	$	-	$	154,669
	Liabilities:
	Contingent purchase consideration		$	-		$	-	$	19,233	$	19,233
	Total liabilities		$	-		$	-	$	19,233	$	19,233
		At December 31, 2013
	(in thousands)		Level 1			Level 2		Level 3		Total
	Assets:
	Investment in money market funds (1)		$	37,701		$	-	$	-	$	37,701
	Total assets		$	37,701		$	-	$	-	$	37,701
	Liabilities:
	Contingent purchase consideration		$	-		$	-	$	16,619	$	16,619
	Total liabilities		$	-		$	-	$	16,619	$	16,619
	(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)	'
	The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September 30, 2014.
	(in thousands)
	Balance at December 31, 2013		$	16,619
	Expense (income) included in earnings			3,216
	Settlements			(1,691	)
	Purchases, sales and issuances			1,089
	Transfers in/(out) of Level 3			-
	Balance at September 30, 2014		$	19,233

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventories [Abstract]	'
Inventories	'
	Inventories consist of the following:
		September 30,		December 31,
	(in thousands)	2014		2013
	Raw materials and supplies	$	16,089	$	2,656
	Work-in-process		31,383		9,819
	Finished goods		15,061		2,168
	Total inventories	$	62,533	$	14,643

Intangible_assets_inprocess_re1

Intangible assets, in-process research and development and goodwill (Tables)	9 Months Ended
	Sep. 30, 2014
Intangible assets, in-process research and development and goodwill [Abstract]	'
Intangible Assets	'
	Intangible assets consist of the following:
					Manufacturing			Corporate			Marketed			Licensed			Biodefense			Contract
	(in thousands)	RSDL			Agreement			Tradename			Products			Products			Products			Manufacturing			Total
	Cost basis
	Balance at December 31, 2013	$	28,621		$	3,478		$	-		$	-		$	-		$	-		$	-		$	32,099
	Additions		-			-			2,800			8,300			3,300			20,400			5,600			40,400
	Balance at September 30, 2014	$	28,621		$	3,478		$	2,800		$	8,300		$	3,300			20,400		$	5,600		$	72,499
	Accumulated amortization
	Balance at December 31, 2013	$	(1,468	)	$	(483	)	$	-		$	-		$	-		$	-		$	-		$	(1,951	)
	Amortization		(2,640	)		(870	)		(338	)		(502	)		(285	)		(1,026	)		(423	)		(6,084	)
	Balance at September 30, 2014	$	(4,108	)	$	(1,353	)	$	(338	)	$	(502	)	$	(285	)	$	(1,026	)	$	(423	)	$	(8,035	)
	Net book value at September 30, 2014	$	24,513		$	2,125		$	2,462		$	7,798		$	3,015		$	19,374			5,177		$	64,464
Goodwill	'
	The following table is a summary of changes in goodwill:
	(in thousands)	Total
	Cost basis
	Balance at December 31, 2013	$	13,954
	Additions		27,347
	Balance at September 30, 2014	$	41,301

Equity_awards_Tables

Equity awards (Tables)	9 Months Ended
	Sep. 30, 2014
Equity awards [Abstract]	'
Option Award Activity	'
	As of September 30, 2014, the Company had two stock-based employee compensation plans, the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan") (together, the "Emergent Plans").
	On May 22, 2014, the Company's shareholders approved an amendment to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 4,000,000. As part of this amendment, awards of restricted stock units granted after May 22, 2014 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 2.3 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 1,000,000.
	The following is a summary of stock option award activity under the Emergent Plans:
		2006 Plan					2004 Plan
		Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
	Outstanding at December 31, 2013		3,633,146		$	17.01		53,156	$	8.86	$	23,148,738
	Granted		1,116,721			27.49		-		-
	Exercised		(663,256	)		16.66		-		-
	Forfeited		(92,549	)		19.69		-		-
	Outstanding at September 30, 2014		3,994,062		$	19.94		53,156	$	8.86	$	14,289,421
	Exercisable at September 30, 2014		2,086,114		$	17.76		53,156	$	8.86	$	9,446,930
Restricted Stock Units Activity	'
	The following is a summary of restricted stock unit award activity under the 2006 Plan:
		Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
	Outstanding at December 31, 2013		789,951		$	16.53	$	18,246,611
	Granted		558,362			27.49
	Vested		(345,072	)		17.76
	Forfeited		(44,275	)		19.66
	Outstanding at September 30, 2014		958,966		$	22.32	$	20,435,565

Earnings_per_share_Tables

Earnings per share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings per share [Abstract]	'
Summary of Basic and Diluted Net Income per Share	'
	For the three and nine month periods ended September 30, 2014 and 2013, basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period.
	For the three and nine month periods ended September 30, 2014, diluted earnings per share is computed using the if-converted method by dividing the adjusted net income by the weighted average number of shares of common stock outstanding during the period. The adjusted net income is adjusted for interest expense and amortization of debt issuance cost, both net of tax, associated with the Company's Notes. The weighted average number of shares-diluted is adjusted for the potential dilutive effect of the exercise of stock options and the vesting of restricted stock units along with the assumption of the conversion of the Notes, at the beginning of the period.
	For the three and nine months ended September 30, 2013, diluted earnings per share is computed using the treasury method by dividing net income by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised.
	The following table presents the calculation of basic and diluted net income per share:
		Three Months Ended September 30,				Nine Months Ended September 30,
	(in thousands, except share and per share data)	2014		2013		2014		2013
	Numerator:
	Net income	$	21,832	$	13,491	$	6,625	$	15,913
	Interest expense applicable to convertible debt, net of tax		917		-		-		-
	Amortization of debt issuance costs, net of tax		203		-		-		-
	Adjusted net income	$	22,952	$	13,491	$	6,625	$	15,913
	Denominator:
	Weighted-average number of shares—basic		37,507,220		36,272,579		37,261,357		36,129,183
	Dilutive securities—equity awards		954,639		742,950		623,837		375,047
	Dilutive securities—convertible debt		8,095,304		-		-		-
	Weighted-average number of shares—diluted		46,557,163		37,015,529		37,885,194		36,504,230
	Income per share-basic	$	0.58	$	0.37	$	0.18	$	0.44
	Income per share-diluted	$	0.49	$	0.36	$	0.17	$	0.44

Segment_information_Tables

Segment information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment information [Abstract]	'
Segment Information	'
	The Biodefense division is a specialty biopharmaceutical business focused on countermeasures that address Chemical, Biological, Radiological and Nuclear threats and consists of two business units: vaccines and therapeutics, and medical devices. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets hematology/oncology, transplantation and infectious diseases, and consists of three business units, therapeutics, vaccines and contract manufacturing. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.
		Reportable Segments
	(in thousands)	Biodefense		Biosciences			All Other			Total
	Three Months Ended September 30, 2014
	External revenue	$	104,130	$	33,824		$	-		$	137,954
	Net income (loss)		25,182		(496	)		(2,854	)		21,832
	Three Months Ended September 30, 2013
	External revenue	$	89,102	$	-		$	-		$	89,102
	Net income (loss)		27,175		(12,491	)		(1,193	)		13,491
	Nine Months Ended September 30, 2014
	External revenue	$	243,162	$	59,001		$	-		$	302,163
	Net income (loss)		56,305		(43,321	)		(6,359	)		6,625
	Nine Months Ended September 30, 2013
	External revenue	$	213,663	$	975		$	-		$	214,638
	Net income (loss)		56,780		(38,019	)		(2,848	)		15,913

Summary_of_significant_account2

Summary of significant accounting policies (Details)	9 Months Ended
	Sep. 30, 2014
	Criteria
Summary of significant accounting policies [Abstract]	'
Basic criteria for revenue recognition	4

Acquisitions_Details

Acquisitions (Details) (USD $)

3 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 01, 2013

Sep. 30, 2014

Sep. 30, 2014

Feb. 21, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Dec. 11, 2013

Feb. 21, 2014

Feb. 21, 2014

Feb. 21, 2014

Sep. 30, 2014

Feb. 21, 2014

Sep. 30, 2014

Feb. 21, 2014

Aug. 01, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Aug. 01, 2013

Aug. 01, 2013

Sep. 30, 2014

Aug. 01, 2013

Aug. 01, 2013

Corporate Trade Name [Member]

Licensed Products [Member]

Biosciences [Member]

Biodefense [Member]

Contract Manufacturing [Member]

RSDL [Member]

Manufacturing Agreement [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

Cangene [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

HPPD [Member]

Corporate Trade Name [Member]

Marketed Products [Member]

Licensed Products [Member]

Biosciences [Member]

Biodefense [Member]

Biodefense [Member]

Contract Manufacturing [Member]

Minimum [Member]

Maximum [Member]

Biodefense [Member]

RSDL [Member]

Manufacturing Agreement [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price paid per share of acquisition (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated Purchase Price [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash

'

'

'

'

'

'

'

'

'

$43,631,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts receivable

'

'

'

'

'

'

'

'

'

19,649,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory

'

'

'

'

'

'

'

'

'

52,619,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid expenses and other assets

'

'

'

'

'

'

'

'

'

2,375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, plant and equipment

'

'

'

'

'

'

'

'

'

40,264,000

'

'

'

'

'

'

'

'

'

'

'

1,543,000

'

'

'

'

'

'

'

'

Deferred taxes, net

'

'

'

'

'

'

'

'

'

18,371,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income tax receivable

'

'

'

'

'

'

'

'

'

2,940,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued liabilities and Accounts Payable

'

'

'

'

'

'

'

'

'

-22,918,000

'

'

'

'

'

'

'

'

'

'

'

-1,464,000

'

'

'

'

'

'

'

'

Provision for chargebacks

'

'

'

'

'

'

'

'

'

-2,447,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration

'

'

'

'

'

'

'

'

'

-1,089,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

'

'

'

'

'

'

'

'

'

-6,378,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of tangible assets acquired and liabilities assumed

'

'

'

'

'

'

'

'

'

147,017,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of cash paid to Bracco Diagnostics, Inc.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,873,000

'

'

'

'

'

'

'

'

Contingent purchase consideration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,232,000

'

'

'

'

'

'

'

'

Acquired in-process research and development

'

'

'

'

'

'

'

'

'

8,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired intangible assets

'

'

'

'

'

'

3,500,000

'

'

40,400,000

'

'

'

'

2,800,000

8,300,000

3,300,000

'

20,400,000

'

5,600,000

32,099,000

'

'

'

'

'

'

28,600,000

'

Goodwill

41,301,000

13,954,000

'

'

'

'

'

'

'

25,883,000

'

'

'

'

'

'

'

'

'

'

'

9,916,000

'

'

'

'

'

'

'

'

Other

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,000

'

'

'

'

'

'

'

'

Total purchase price

'

'

'

'

'

'

'

'

'

221,800,000

'

'

'

'

'

'

'

'

'

'

'

42,105,000

'

42,105,000

'

'

'

'

'

'

Step up adjustment to inventory

'

'

'

'

'

'

'

'

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization period of step up adjustment

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible Assets Acquired [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'10 years

'7 years

'

'12 years

'

'8 years

'8 years

'

'115 months

'

'

'

'

'

'3 years

Transaction costs

'

'

'

'

'

'

'

'

'

'

3,700,000

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inception to date transaction costs

'

'

'

'

'

'

'

'

'

'

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Pro Forma Information [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pro forma revenue

'

'

'

'

'

'

'

'

'

'

'

329,642,000

304,164,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pro forma net income

'

'

'

'

'

'

'

'

'

'

'

9,109,000

468,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, percentage of RSDL net sales (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

10.00%

'

'

'

Amortization for intangible assets

-6,084,000

'

-338,000

-285,000

620,000

425,000

'

-2,640,000

-870,000

'

2,600,000

1,000,000

'

'

'

'

'

1,500,000

'

1,000,000

'

'

'

1,200,000

3,500,000

'

'

0

'

'

Weighted average amortization period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'77 months

'

'

'

'

'

'

Present value discount rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

16.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognized revenues

'

'

'

'

'

'

'

'

'

'

'

82,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss attributable to Emergent BioSolutions Inc.

'

'

'

'

'

'

'

'

'

'

'

4,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Other Changes

'

'

'

'

'

'

'

'

'

'

'

$5,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Acquired inventory reflects a $6.2 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $6.2 million step-up was estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on estimated inventory turnover, which will increase costs of product sales and contract manufacturing during such period.

Fair_value_measurements_Detail

Fair value measurements (Details) (USD $)

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Measurements, Recurring [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Assets:

'

'

'

'

'

'

'

'

'

'

Investment in money market funds (1)

'

'

$154,669,000

[1]

$37,701,000

[1]

$154,669,000

[1]

$37,701,000

[1]

$0

[1]

$0

[1]

$0

[1]

$0

[1]

Total assets

'

'

154,669,000

37,701,000

154,669,000

37,701,000

0

0

0

0

Liabilities:

'

'

'

'

'

'

'

'

'

'

Contingent purchase consideration

'

'

19,233,000

16,619,000

0

0

0

0

19,233,000

16,619,000

Total liabilities

'

'

19,233,000

16,619,000

0

0

0

0

19,233,000

16,619,000

Unobservable Input Reconciliation [Roll Forward]

'

'

'

'

'

'

'

'

'

'

Balance, beginning of period

'

16,619,000

'

'

'

'

'

'

'

'

Expense (income) included in earnings

'

3,216,000

'

'

'

'

'

'

'

'

Settlements

'

-1,691,000

'

'

'

'

'

'

'

'

Purchases, sales and issuances

'

1,089,000

'

'

'

'

'

'

'

'

Transfers in/(out) of Level 3

'

0

'

'

'

'

'

'

'

'

Balance, end of period

19,233,000

19,233,000

'

'

'

'

'

'

'

'

Change in fair value of contingent obligations

$1,600,000

$3,200,000

'

'

'

'

'

'

'

'

[1]

Included in cash and cash equivalents in accompanying consolidated balance sheets.

MorphoSys_Collaboration_Agreem1

MorphoSys Collaboration Agreement (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Morphosys [Member]
			AccountingUnit
Collaborative arrangements [Line Items]	'	'	'
Non refundable receipt	'	'	$20,000,000
Additional contingent payment that may be received	'	'	163,000,000
Description of rights and obligations	'	'	'MorphoSys and the Company will jointly fund further development of MOR209/ES414, with the Company responsible for 36% of the total development cost and MorphoSys responsible for the remainder
Funding requirement cap	'	'	186,000,000
Tiered royalty obligation (in hundredths)	'	'	20.00%
Number of units of accounting	'	'	2
Proceeds allocated to two units of accounting	'	'	20,000,000
Proceeds allocated to license	'	'	15,300,000
Proceeds allocated to development services	'	'	4,700,000
Present value factor for estimating selling price of license (in hundredths)	'	'	12.00%
Present value factor for estimating selling price of research and development services (in hundredths)	'	'	12.00%
Revenue from license fee	'	'	15,300,000
Accounts receivable	'	'	450,000
Current deferred revenue	5,813,000	1,834,000	590,000
Long-term deferred revenue	$5,815,000	$0	$4,100,000

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials and supplies	$16,089	$2,656
Work-in-process	31,383	9,819
Finished goods	15,061	2,168
Total inventories	$62,533	$14,643

Intangible_assets_inprocess_re2

Intangible assets, in-process research and development and goodwill (Details) (USD $)	3 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	$32,099,000
Additions	40,400,000	'
Intangible Assets, Ending Balance	72,499,000	32,099,000
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	-1,951,000
Amortization	-6,084,000	'
Accumulated Amortization, Ending Balance	-8,035,000	-1,951,000
Net book value of intangible assets	64,464,000	'
Goodwill, Cost Basis [Abstract]	'	'
Goodwill, Beginning Balance	'	13,954,000
Goodwill, Additions	27,347,000	'
Goodwill, Ending Balance	41,301,000	13,954,000
Goodwill, net book value	41,301,000	13,954,000
RSDL [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	28,621,000
Additions	0	'
Intangible Assets, Ending Balance	28,621,000	28,621,000
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	-1,468,000
Amortization	-2,640,000	'
Accumulated Amortization, Ending Balance	-4,108,000	-1,468,000
Net book value of intangible assets	24,513,000	'
Manufacturing Agreement [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	3,478,000
Additions	0	'
Intangible Assets, Ending Balance	3,478,000	3,478,000
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	-483,000
Amortization	-870,000	'
Accumulated Amortization, Ending Balance	-1,353,000	-483,000
Net book value of intangible assets	2,125,000	'
Corporate Tradename [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	0
Additions	2,800,000	'
Intangible Assets, Ending Balance	2,800,000	0
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	0
Amortization	-338,000	'
Accumulated Amortization, Ending Balance	-338,000	0
Net book value of intangible assets	2,462,000	'
Marketed Products [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	0
Additions	8,300,000	'
Intangible Assets, Ending Balance	8,300,000	0
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	0
Amortization	-502,000	'
Accumulated Amortization, Ending Balance	-502,000	0
Net book value of intangible assets	7,798,000	'
Licensed Products [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	0
Additions	3,300,000	'
Intangible Assets, Ending Balance	3,300,000	0
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	0
Amortization	-285,000	'
Accumulated Amortization, Ending Balance	-285,000	0
Net book value of intangible assets	3,015,000	'
Biodefense Products [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	0
Additions	20,400,000	'
Intangible Assets, Ending Balance	20,400,000	0
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	0
Amortization	-1,026,000	'
Accumulated Amortization, Ending Balance	-1,026,000	0
Net book value of intangible assets	19,374,000	'
Contract Manufacturing [Member]	'	'
Cost Basis [Abstract]	'	'
Intangible Assets, Beginning Balance	'	0
Additions	5,600,000	'
Intangible Assets, Ending Balance	5,600,000	0
Accumulated Amortization [Abstract]	'	'
Accumulated Amortization, Beginning Balance	'	0
Amortization	-423,000	'
Accumulated Amortization, Ending Balance	-423,000	0
Net book value of intangible assets	5,177,000	'
Biosciences [Member] | Biosciences Therapeutics [Member]	'	'
Accumulated Amortization [Abstract]	'	'
Net book value of intangible assets	50,300,000	'
Biosciences [Member] | Otlertuzumab [Member]	'	'
Accumulated Amortization [Abstract]	'	'
Net book value of intangible assets	41,800,000	'
Biosciences [Member] | IXINITY product candidates [Member]	'	'
Accumulated Amortization [Abstract]	'	'
Net book value of intangible assets	$8,500,000	'

Longterm_debt_Details

Long-term debt (Details) (USD $)	9 Months Ended			12 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended	1 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Jan. 29, 2014	Sep. 30, 2014
			BAML Revolving Credit Facility [Member]	BAML Revolving Credit Facility [Member]	Credit Agreement [Member]	Credit Agreement [Member]	Credit Agreement [Member]	Credit Agreement [Member]	2.875% Convertible Senior Notes Due 2021 [Member]	BAML Term Loan [Member]
					Institution
Long-Term Debt [Line Items]	'	'	'	'	'	'	'	'	'	'
Face amount of debt instrument	'	'	'	'	'	'	'	'	$250,000,000	'
Interest rate, stated percentage (in hundredths)	'	'	'	'	'	'	'	'	2.88%	'
Maturity date	'	'	11-Dec-18	'	'	'	'	'	15-Jan-21	11-Dec-18
Conversion rate of notes per $1,000 principal amount (in shares)	'	'	'	'	'	'	'	'	30.8821	'
Conversion price per share (in dollars per share)	'	'	'	'	'	'	'	'	$32.38	'
Debt issuance costs	'	'	'	'	'	'	'	'	8,300,000	'
Number of lending institutions	'	'	'	'	3	'	'	'	'	'
Maximum borrowing capacity	'	'	100,000,000	'	'	'	'	'	'	125,000,000
Proceeds from borrowings on long-term indebtedness	'	'	'	62,000,000	'	'	'	'	'	'
Payments on borrowings on long-term indebtedness	62,000,000	3,352,000	62,000,000	'	'	'	'	'	'	'
Debt covenant, consolidated debt service coverage ratio, minimum	'	'	'	'	'	'	2.5	'	'	'
Debt covenant, leverage ratio, maximum	'	'	'	'	'	3.5	4	3.75	'	'
Debt Instrument, covenant, senior leverage ratio, maximum	'	'	'	'	'	'	2	'	'	'
Debt covenant, minimum cash and liquid investments balance	'	'	'	'	$50,000,000	'	$50,000,000	'	'	'

Equity_awards_Details

Equity awards (Details) (USD $)	9 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
	Restricted Stock Units (RSUs) [Member]	Stock Options Member [Member]	Stock Options Member [Member]	2006 Plan [Member]	2004 Plan [Member]
				Stock Options Member [Member]	Stock Options Member [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee	'	'	'	1,000,000	'
Options outstanding [Roll Forward]	'	'	'	'	'
Outstanding, beginning of period (in shares)	'	'	'	3,633,146	53,156
Granted (in shares)	'	'	'	1,116,721	0
Exercised (in shares)	'	'	'	-663,256	0
Forfeited (in shares)	'	'	'	-92,549	0
Outstanding, end of period (in shares)	'	'	'	3,994,062	53,156
Exercisable, end of period (in shares)	'	'	'	2,086,114	53,156
Weighted-Average Exercise Price [Roll Forward]	'	'	'	'	'
Outstanding, beginning of period (in dollars per share)	'	'	'	$17.01	$8.86
Granted (in dollars per share)	'	'	'	$27.49	$0
Exercised (in dollars per share)	'	'	'	$16.66	$0
Forfeited (in dollars per share)	'	'	'	$19.69	$0
Outstanding, end of period (in dollars per share)	'	'	'	$19.94	$8.86
Exercisable, end of period (in dollars per share)	'	'	'	$17.76	$8.86
Aggregate Intrinsic Value [Abstract]	'	'	'	'	'
Outstanding, beginning of period	'	$14,289,421	$23,148,738	'	'
Outstanding, end of period	'	14,289,421	23,148,738	'	'
Exercisable, end of period	'	9,446,930	'	'	'
Restricted stock unit award activity [Roll Forward]	'	'	'	'	'
Outstanding, beginning of period (in shares)	789,951	'	'	'	'
Granted (in shares)	558,362	'	'	'	'
Vested (in shares)	-345,072	'	'	'	'
Forfeited (in shares)	-44,275	'	'	'	'
Outstanding, end of period (in shares)	958,966	'	'	'	'
Weighted-Average Grant Price [Roll Forward]	'	'	'	'	'
Outstanding, beginning of period (in dollars per share)	$16.53	'	'	'	'
Granted (in dollars per share)	$27.49	'	'	'	'
Vested (in dollars per share)	$17.76	'	'	'	'
Forfeited (in dollars per share)	$19.66	'	'	'	'
Outstanding, end of period (in dollars per share)	$22.32	'	'	'	'
Aggregate intrinsic value [Abstract]	'	'	'	'	'
Outstanding, beginning of period	18,246,611	'	'	'	'
Outstanding, end of period	$20,435,565	'	'	'	'
Restricted stock unit conversion ratio	'	'	'	2.3	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	'	'	'	4,000,000	'

Variable_interest_entities_Det

Variable interest entities (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Selling, General and Administrative Expenses [Member] | Biosciences [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Adjustment to noncontrolling interest	$453,000	'
Oxford Emergent Tuberculosis Consortium [Member]	'	'
Variable Interest Entity [Line Items]	'	'
Adjustment to noncontrolling interest	$0	$0

Earnings_per_share_Details

Earnings per share (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net income	$21,832	$13,491	$6,625	$15,913
Interest expense applicable to convertible debt, net of tax	917	0	0	0
Amortization of debt issuance costs, net of tax	203	0	0	0
Adjusted net loss	$22,952	$13,491	$6,625	$15,913
Denominator:	'	'	'	'
Weighted-average number of shares-basic (in shares)	37,507,220	36,272,579	37,261,357	36,129,183
Dilutive securities-equity awards (in shares)	954,639	742,950	623,837	375,047
Weighted-average number of shares-diluted (in shares)	46,557,163	37,015,529	37,885,194	36,504,230
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities	8,095,304	0	0	0
Income per share - basic	$0.58	$0.37	$0.18	$0.44
Income per share-diluted	$0.49	$0.36	$0.17	$0.44
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive shares excluded from calculation (in shares)	1,500,000	1,400,000	1,500,000	1,500,000
Convertible debt [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive shares excluded from calculation (in shares)	'	'	8,100,000	'

Segment_information_Details

Segment information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			Segment
			BusinessUnit
Segment Reporting Information [Line Items]	'	'	'	'
Number of business segments	'	'	2	'
Number of business units	'	'	3	'
External revenue	$137,954	$89,102	$302,163	$214,638
Net income	21,832	13,491	6,625	15,913
Biodefense [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
External revenue	104,130	89,102	243,162	213,663
Net income	25,182	27,175	56,305	56,780
Biosciences [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
External revenue	33,824	0	59,001	975
Net income	-496	-12,491	-43,321	-38,019
All Other [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
External revenue	0	0	0	0
Net income	($2,854)	($1,193)	($6,359)	($2,848)

Subsequent_Event_Details

Subsequent Event (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2015
Subsequent Event (Details) [Abstract]	'
Restructuring Charges	$5